Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study.
暂无分享，去创建一个
D. Schadendorf | M. Ross | P. Ascierto | J. Kirkwood | M. Del Vecchio | J. Grob | P. Rutkowski | V. Chiarion-Sileni | G. Long | M. Carlino | J. Luke | P. Mohr | C. Krepler | Z. Eroglu | F. Spagnolo | A. Eggermont | J. Mackiewicz | Ruixuan Jiang | M. A. Khattak | L. de la Cruz Merino | C. Robert | Ke Chen | F. de Galitiis | M. Fukunaga-Kalabis